Search


Health Canada Guidance: Nitrosamine Impurities in Medications
Health Canada has updated its guidance on evaluating and managing N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products. Originally published on 4 April 2022 and updated on 5 November 2026, the guidance outlines expectations for market authorization holders (MAHs), applicants and manufacturers regarding risk assessment, confirmatory testing, acceptable intake (AI) limits and lifecycle risk management. 1. Background and Scope The guidanc

Sharan Murugan
6 days ago4 min read


EMA Updates Nitrosamine Q&A Guidance: New Requirements for Acceptable Intake Limits and Less-Than-Lifetime Exposure
The European Medicines Agency (EMA) has revised its Questions and Answers guidance for marketing authorisation holders (MAHs) and applicants on nitrosamine impurities in human medicinal products. Revision 24, dated 3 November 2026, introduces important clarifications on acceptable intake (AI) limits, less-than-lifetime (LTL) exposure, other N-nitroso compounds and nitrosamines originating from excipients. The update also revises existing recommendations on risk factors, contr

Sharan Murugan
Nov 83 min read


USFDA Guidance: Control of Nitrosamine Impurities in Human Drugs
Earlier today (04 September, 2024) U.S. Food and Drug Administration's Center for Drug Evaluation and Research released the second...

Sharan Murugan
Sep 4, 20242 min read


WHO Guidance: GMP in Preventing and Controlling Nitrosamine Contamination in Pharmaceuticals
Earlier this week, the World Health Organization (WHO) released draft guidelines "WHO Good Manufacturing Practices Considerations for the...

Sharan Murugan
Apr 20, 20242 min read


MHRA Guidance: MAH Submission of Nitrosamine Risk Evaluation, Risk Assessment and Confirmatory Testing
Nitrosamines have become a significant concern in the pharmaceutical industry due to their potential carcinogenicity. In response to this...

Sharan Murugan
Jan 18, 20242 min read


USFDA Guidance: Recommended Acceptable Intake Limits for Nitrosamine DS-Related Impurities
Today (04 August 2023) the United States Food & Drug Administration's Center for Biologics Evaluation and Research and Center for Drug...

Sharan Murugan
Aug 4, 20232 min read


Canada HC Guidance: Nitrosamine Impurities in Medications
Last Friday (28 July, 2023) Health Canada published an updated "Guidance on Nitrosamine Impurities in Medications" that details about...

Sharan Murugan
Jul 30, 20231 min read


Malaysia’s NPRA: Guideline on Manufacturer’s, Import, Wholesaler’s Licenses & Nitrosamine Impurity
Today (12 July, 2023) the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia published a guideline on "Application of...

Sharan Murugan
Jul 12, 20231 min read


Health Canada: Guidance on Nitrosamine Impurities in Medications
Health Canada last week published an updated "Guidance on Nitrosamine Impurities in Medications" that details about on Evaluating and...

Sharan Murugan
Apr 23, 20231 min read


UK MHRA: Guidance on EC Decision Reliance Procedure Extended till 31 Dec, 2023 & Nitrosamine Risk
On 18th November 2022 the UK's Medicines and Healthcare products Regulatory Agency released its updated guidance on the "European...

Sharan Murugan
Nov 19, 20221 min read


Europe's EDQM: Nitrosamines – Deadline Extension for all CEP Holders - Now 1 October 2023
Nitrosamines are chemical compounds classified as probable human carcinogens on the basis of animal studies. EU regulators first became...

Sharan Murugan
Aug 12, 20221 min read
